Clinical Trial Update: Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating extended dosing of Macugen (pegaptanib sodium) for proliferative diabetic retinopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Diabetic Retinopathy

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Valley Retina Institute | Conditions: Proliferative Diabetic Retinopathy | Phase 4 | Status: UNKNOWN